AU2021262588A1 - Imidazopyrimidines as modulators of IL-17 - Google Patents

Imidazopyrimidines as modulators of IL-17 Download PDF

Info

Publication number
AU2021262588A1
AU2021262588A1 AU2021262588A AU2021262588A AU2021262588A1 AU 2021262588 A1 AU2021262588 A1 AU 2021262588A1 AU 2021262588 A AU2021262588 A AU 2021262588A AU 2021262588 A AU2021262588 A AU 2021262588A AU 2021262588 A1 AU2021262588 A1 AU 2021262588A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021262588A
Other languages
English (en)
Inventor
Steven Goldberg
Connor Martin
Timothy B. RHORER
Virginia M. Tanis
Xiaohua XUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2021262588A1 publication Critical patent/AU2021262588A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
AU2021262588A 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of IL-17 Abandoned AU2021262588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063017679P 2020-04-30 2020-04-30
US63/017,679 2020-04-30
PCT/IB2021/053517 WO2021220183A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of il-17

Publications (1)

Publication Number Publication Date
AU2021262588A1 true AU2021262588A1 (en) 2023-01-19

Family

ID=75769661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021262588A Abandoned AU2021262588A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of IL-17

Country Status (11)

Country Link
US (1) US12559496B2 (https=)
EP (1) EP4143193B1 (https=)
JP (1) JP7661361B2 (https=)
KR (1) KR20230018387A (https=)
CN (1) CN115867348B (https=)
AU (1) AU2021262588A1 (https=)
BR (1) BR112022021957A2 (https=)
CA (1) CA3181793A1 (https=)
IL (1) IL297734A (https=)
MX (1) MX2022013650A (https=)
WO (1) WO2021220183A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284283B2 (en) * 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080131B1 (en) * 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
US10152431B2 (en) 2015-03-16 2018-12-11 Honeywell International Inc. System and method for remote set-up and adjustment of peripherals
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
IL279348B2 (en) * 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
JP7349491B2 (ja) * 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
MX2022013637A (es) 2020-04-30 2022-11-16 Janssen Pharmaceutica Nv Nuevos compuestos de triazinoindol.
MX2022013649A (es) 2020-04-30 2023-02-01 Janssen Pharmaceutica Nv Métodos para identificar moduladores de la ruta de il-17.

Also Published As

Publication number Publication date
EP4143193A1 (en) 2023-03-08
WO2021220183A1 (en) 2021-11-04
CN115867348B (zh) 2025-05-06
KR20230018387A (ko) 2023-02-07
EP4143193B1 (en) 2026-04-22
IL297734A (en) 2022-12-01
CN115867348A (zh) 2023-03-28
MX2022013650A (es) 2023-02-01
JP2023523770A (ja) 2023-06-07
JP7661361B2 (ja) 2025-04-14
US20230242537A1 (en) 2023-08-03
BR112022021957A2 (pt) 2023-01-17
CA3181793A1 (en) 2021-11-04
US12559496B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
US12559496B2 (en) Imidazopyrimidines as modulators of IL-17
US12024524B2 (en) Imidazopyridazines as modulators of IL-17
JP7441264B2 (ja) Ｊａｋファミリーのキナーゼの阻害剤としてのイミダゾピロロピリジン
US10961228B2 (en) JAK1 selective inhibitors
JP7671796B2 (ja) Ｃｏｔモジュレーター及びその使用方法
JP7042804B2 (ja) ピペラジンカルバメート、及びその製造と使用の方法
JP6623270B2 (ja) Ｒｏｒγｔのモジュレーターとしてのトリフルオロメチルアルコール
WO2022038365A9 (en) Fumarate derivatives and their medical use
US6710064B2 (en) Hydantoin compounds useful as anti-inflammatory agents
KR20240082371A (ko) 이미다조피리다진 il-17 억제제 화합물
KR20240115978A (ko) Lpa 수용체 길항제 및 이의 용도
JP2015520217A (ja) ２ｈ−イミダゾール−４−アミン化合物およびｂａｃｅ阻害物質としてのその使用
JP7159161B2 (ja) β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法
EP1367058B1 (en) Tetrahydropyran derivatives
JP2023513121A (ja) Ａｄａｍｔｓ阻害剤、その製造および医薬用途
US20250188079A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
JP7333321B2 (ja) 免疫プロテアソーム阻害剤
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period